Literature DB >> 22517240

Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease.

Francesc Casellas1, Manuel Barreiro de Acosta, Marta Iglesias, Virginia Robles, Pilar Nos, Mariam Aguas, Sabino Riestra, Ruth de Francisco, Michel Papo, Natalia Borruel.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is a debilitating immune disorder that impairs function and health-related quality of life (HRQOL). A goal of IBD treatment is mucosal healing, but it is not known whether it achieves normalization of the patients' perception of health. This can be assessed by using a cut-off scoring threshold of the Inflammatory Bowel Disease Questonnaire-36 (IBDQ-36). AIMS: To determine whether patients with Crohn's disease (CD) and ulcerative colitis (UC) in clinical remission and with mucosal healing normalize their HRQOL.
METHODS: This is a multicentric, prospective, observational, cross-sectional study of patients who are in stable clinical remission and having mucosal healing. Patients completed the IBDQ-36, the EuroQol-5D, and the Daily Fatigue Impact Scale fatigue questionnaires. Complete restoration of health was believed to have occurred when the global score in the IBDQ-36 was at least 209 points.
RESULTS: A total of 115 patients (48 with CD, 67 with UC) were included. The median activity index (the Harvey-Bradshaw or the colitis activity index) was 1.0 and the median endoscopic index (Simple Endoscopic Score for Crohn's disease or Mayo) was 0. Eighty percent of the patients (79% in CD and 82% in UC patients, P=NS) normalized their HRQOL. Type of treatment was not related to normalization of HRQOL. The lack of restoration of health was significantly related to fatigue and anxiety/depression.
CONCLUSION: Mucosal healing is associated with a normalization of the perception of health by most IBD patients independently of treatment. However, a significant group of patients do not achieve restoration of HRQOL, which reinforces the necessity of a global care addressed to all patient concerns to achieve patients' complete health restoration.

Entities:  

Mesh:

Year:  2012        PMID: 22517240     DOI: 10.1097/MEG.0b013e32835414b2

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  28 in total

Review 1.  Colitis-induced neuroplasticity disrupts motility in the inflamed and post-inflamed colon.

Authors:  Gary M Mawe
Journal:  J Clin Invest       Date:  2015-03-02       Impact factor: 14.808

2.  Expressions of E-cadherin, p120ctn, β-catenin and NF-κB in ulcerative colitis.

Authors:  Chao Zhang; Li-Wei Liu; Wen-Jia Sun; Sheng-Hui Qin; Ling-Zhi Qin; Xi Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

3.  Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse.

Authors:  Jun Shen; Yuqi Qiao; Zhihua Ran; Tianrong Wang; Jiangtao Xu; Jinsun Feng
Journal:  Int J Clin Exp Pathol       Date:  2013-04-15

4.  Assessing disease activity in patients with ulcerative colitis.

Authors:  Alissa Walsh; Simon Travis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-11

5.  Patient-Reported Outcomes Measurement Information System in Children with Crohn's Disease.

Authors:  Marina Arvanitis; Darren A DeWalt; Christopher F Martin; Millie D Long; Wenli Chen; Beth Jaeger; Robert S Sandler; Michael D Kappelman
Journal:  J Pediatr       Date:  2016-05-02       Impact factor: 4.406

Review 6.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

7.  The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth.

Authors:  Joseph D Frasca; Adam S Cheifetz
Journal:  Ann Transl Med       Date:  2019-12

Review 8.  Mucosal healing in inflammatory bowel disease: Expanding horizon.

Authors:  Jimil Shah; Manik Lal Thakur; Usha Dutta
Journal:  Indian J Gastroenterol       Date:  2019-04-29

9.  The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Authors:  Aaron Yarlas; Mary Kaye Willian; Arpita Nag
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

Review 10.  Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment.

Authors:  Cristina Calviño-Suárez; Rocío Ferreiro-Iglesias; Iria Bastón-Rey; Manuel Barreiro-de Acosta
Journal:  Int J Environ Res Public Health       Date:  2021-07-04       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.